drugset / Trial / NCT02382874

Allogenic AD-MSC Transplantation in Idiopathic Nephrotic Syndrome (Focal Segmental Glomerulosclerosis)

NCT02382874 ↗

Phase 1 Unknown 5 enrolled Royan Institute
NaSingle-groupOpen-labelTreatment

Summary

Idiopathic Focal Segmental Glumero Sclerosis (FSGS) is not very common but important manifestation of kidney disease. FSGS has poor prognosis among the patterns of Idiopathic Nephrotic Syndrome (INS). Even with treatment (Steroid therapy and cytotoxic immunosuppressant therapy), many patients eventually still require dialysis. Cell therapy is useful in treatment of INS and mesenchymal stromal/stem cell is one of the cells that useful in the treatment of glomerulus disease. Intravenous injection of allogeneic adipose derived mesenchymal stromal/stem cell will be done in 5 patients with refractory INS(FSGS). They will be followed 1, 2, 4 weeks and then monthly until a year following injection day.

Timeline

Start
2015-05
Primary completion
2017-06
Completion
2017-10

Drugs

EvaluationDrugModalityDoseRoute
Subject AdMSC Cell therapy — Intravenous